Targeting monoamine oxidases for the treatment of betel quid dependence: a potential pharmacological and neurobiological approach
Frontiers in Pharmacology · 03.07.2026 · 17
DOI: 10.3389/fphar.2026.1853911 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Frontiers in Pharmacology, online erschienen am 03.07.2026. Verfasst von Sorbomita Chakraborty und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biotechnology, Assam University, Silchar, India. Die Arbeit nennt 66 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Assam University, Silchar.
Abstract (Originalsprache)
The trend of betel quid chewing has witnessed a gradual upsurge in recent years, indicating increased dependence on betel quid/betel-nut and complications of withdrawal. Dedicated efforts towards the development of effective cessation strategies are thus the need of the hour. This review examines the complex relationship between dependence on betel quid with or without tobacco and the activity of monoamine oxidase A, emphasizing a critical yet underexplored area in betel quid addiction. We have analyzed emerging evidence suggesting that arecoline, betel quid’s primary psychoactive constituent, functions as a monoamine oxidase A inhibitor, likely modulating dopaminergic and serotonergic pathways involved in addiction and mood regulation. This inhibitory effect may be pronounced in users who combine betel quid with tobacco, yielding synergistic neurochemical alterations that may enhance dependency. Current treatment approaches largely hinge on behavioral and educational strategies, with minimal pharmacological options available. We propose that understanding the role of monoamine oxidase A in betel quid addiction could pave the way to understanding the complexities of betel quid dependence, especially when consumed with tobacco, and monoamine oxidase A inhibition by the controlled administration of pharmacological inhibitors may serve as a potential strategy for treating withdrawal symptoms and dependence. Future research should include investigating specific monoamine oxidase A expression patterns in betel quid users, developing culturally. Appropriate interventions that integrate biological awareness, and exploring the need for carefully timed monoamine oxidase A inhibitors as cessation aids.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Biotechnology, Assam University, Silchar, India.
- Department of Microbiology, Assam University, Silchar, India.
Förderung
- Assam University, Silchar
Zitieren
APA
Chakraborty, S., Choudhury, A. H., Sharma, I., & Choudhury, Y. (2026). Targeting monoamine oxidases for the treatment of betel quid dependence: a potential pharmacological and neurobiological approach. Frontiers in Pharmacology, 17. https://doi.org/10.3389/fphar.2026.1853911
Vancouver
Chakraborty S, Choudhury AH, Sharma I, Choudhury Y. Targeting monoamine oxidases for the treatment of betel quid dependence: a potential pharmacological and neurobiological approach. Frontiers in Pharmacology. 2026;17. doi:10.3389/fphar.2026.1853911
BibTeX
@article{Chakraborty2026,
author = {Chakraborty, Sorbomita and Choudhury, Abdul Hussain and Sharma, Indu and Choudhury, Yashmin},
title = {Targeting monoamine oxidases for the treatment of betel quid dependence: a potential pharmacological and neurobiological approach},
journal = {Frontiers in Pharmacology},
year = {2026},
volume = {17},
doi = {10.3389/fphar.2026.1853911}
}
EUVIMED